{"id":46434,"date":"2022-07-21T15:01:47","date_gmt":"2022-07-21T13:01:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/"},"modified":"2022-07-21T15:01:47","modified_gmt":"2022-07-21T13:01:47","slug":"intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/","title":{"rendered":"InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes"},"content":{"rendered":"<div>\n<p>SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211;InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that it has expanded its global presence with the opening of multiple new locations in Asia-Pacific and North America. The company\u2019s new facilities include Mandaluyong, Philippines; Kuala Lumpur, Malaysia; Melbourne, Australia; and San Diego, California, adding a large footprint of state-of-the-art laboratories and office space for scaling up InterVenn\u2019s software development, technical support, clinical research and business development.\n<\/p>\n<p>\n\u201cOur global expansion reflects the significant opportunity to apply glycoproteomics to improve clinical decision-making and translational research on a worldwide scale,\u201d said Aldo Carrascoso, CEO of InterVenn Biosciences. \u201cOur new offices and laboratory space will enable us to scale our operations, better connect with biomedical hubs, access local talent and serve different regions with localized resources.\u201d\n<\/p>\n<p>\nWith facilities already established in San Francisco and Southeast Asia, InterVenn is building on its momentum since it was started with the mission that \u201cno one should ever be blindsided by disease.\u201d Each new location will play a key role in the increasing efforts to advance the company on its mission:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>San Diego<\/b> \u2013 InterVenn\u2019s new presence in southern California will give the company access to the thriving San Diego life science community. Corporate business development, sales, marketing and other non-laboratory personnel work out of this new facility.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Australia<\/b> \u2013 InterVenn\u2019s new presence in Melbourne will enable the company to increase scientific collaborations, connect with talent in ML\/AI and informatics, and have broader access to clinical samples and biobanking.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Philippines<\/b> \u2013 InterVenn\u2019s expanded presence in the Philippines will allow the company to scale its software engineering and IT capabilities to support current and future development and commercial activities.\n<\/li>\n<\/ul>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Malaysia<\/b> \u2013 InterVenn\u2019s presence in Malaysia will allow the company to expand its R&amp;D and clinical laboratory functions, enabling footprint expansion into Asia-Pacific. Also, a local Business Development and general administration team will drive regional partnerships, collaborations and commercial activities.\n<\/li>\n<\/ul>\n<p>\nThe company was co-founded by world-renowned scientist and Stanford professor Carolyn Bertozzi, PhD, highly respected innovator and UC Davis professor Carlito LeBrilla, PhD, and Aldo Carrascoso, an expert in AI\/ML and blockchain. InterVenn has developed the world\u2019s first technology platform to interrogate and decode the glycoproteome which will help accelerate the shift from the healthcare industry\u2019s traditional focus on disease management to the new realm of preventive care and health management. The global expansion will support and help accelerate this development and position the company to serve customers with state-of-the-art capabilities.\n<\/p>\n<p>\n<b>About InterVenn Biosciences<\/b>\n<\/p>\n<p>\nInterVenn is a clinical technology company unlocking the value of glycoproteomics for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to significantly improve patient outcomes, but it has remained inaccessible due to its vast complexity. InterVenn is pioneering a new AI-powered platform to decode and unlock the potential of the glycoproteome at clinically meaningful scale for the first time in history. To optimize this entirely new dimension of biology, the company has developed a platform capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.intervenn.com&amp;esheet=52787239&amp;newsitemid=20220721005362&amp;lan=en-US&amp;anchor=www.intervenn.com&amp;index=1&amp;md5=749dd1ae16994ea2c42932539a49c20a\" rel=\"nofollow noopener\" shape=\"rect\">www.intervenn.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nAnthony Petrucci<br \/>\n<br \/>Bioscribe<br \/>\n<br \/><a target=\"_blank\" href=\"mailto&#58;&#97;&#110;&#116;&#104;&#111;&#110;&#x79;&#x40;&#x62;&#x69;&#x6f;&#x73;&#x63;&#x72;&#x69;&#x62;&#x65;&#x2e;com\" rel=\"nofollow noopener\" shape=\"rect\">&#x61;n&#x74;&#104;o&#x6e;&#121;&#x40;&#x62;i&#x6f;&#115;c&#x72;&#105;&#x62;&#101;&#46;&#x63;&#111;m<\/a><br \/>512-581-5442\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211;InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that it has expanded its global presence with the opening of multiple new locations in Asia-Pacific and North America. The company\u2019s new facilities include Mandaluyong, Philippines; Kuala Lumpur, Malaysia; Melbourne, Australia; and San Diego, California, adding a &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46434","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211;InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that it has expanded its global presence with the opening of multiple new locations in Asia-Pacific and North America. The company\u2019s new facilities include Mandaluyong, Philippines; Kuala Lumpur, Malaysia; Melbourne, Australia; and San Diego, California, adding a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-21T13:01:47+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes\",\"datePublished\":\"2022-07-21T13:01:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\\\/\"},\"wordCount\":580,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\\\/\",\"name\":\"InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-07-21T13:01:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/","og_locale":"en_US","og_type":"article","og_title":"InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes - Pharma Trend","og_description":"SAN FRANCISCO&#8211;(BUSINESS WIRE)&#8211;InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced that it has expanded its global presence with the opening of multiple new locations in Asia-Pacific and North America. The company\u2019s new facilities include Mandaluyong, Philippines; Kuala Lumpur, Malaysia; Melbourne, Australia; and San Diego, California, adding a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-21T13:01:47+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes","datePublished":"2022-07-21T13:01:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/"},"wordCount":580,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/","url":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/","name":"InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-07-21T13:01:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/intervenn-expands-global-presence-to-drive-the-potential-of-glycoproteomics-to-improve-patient-outcomes\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"InterVenn Expands Global Presence to Drive the Potential of Glycoproteomics to Improve Patient Outcomes"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46434"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46434\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}